 Shares of Morphic Holdings shot up today after the biopharmaceutical company announced an agreement to be acquired by Eli Lilly in a cash deal valued at roughly $3.2 billion. Lilly says the acquisition would improve outcomes for patients with inflammatory bowel disease. Morphic stock jumped more than 76% in pre-market trading.